57th ASH Annual Meeting and Exposition (December 5-8, 2015): 615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: New Approaches Using Older Drugs

Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation Oral and Poster Abstracts
Oral

W109, Level 1 (Orange County Convention Center)

Moderators:

Jessica K. Altman, MD, Northwestern University and Eytan M Stein, M.D., Memorial Sloan Kettering Cancer Center

Disclosures:

Altman: Astellas: Other: Advisory board; assistance with abstract preparation ; BMS: Other: Advisory board ; Novartis: Other: Advisory board ; Spectrum: Other: Advisory board ; Ariad: Other: Advisory board ; Seattle Genetics: Other: Advisory board . Stein: Seattle Genetics, Inc.: Membership on an entity’s Board of Directors or advisory committees ; Agios: Membership on an entity’s Board of Directors or advisory committees .

9:30 AM

217

North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)

James M. Foran, MD¹, Zhuoxin Sun, PhD²^*, David F. Claxton, MD³, Hillard M. Lazarus, MD⁴, Mary L. Thomas, RN, MS⁵^*, Ari Melnick, MD⁶, Ross L. Levine, MD⁷, Elisabeth Paietta, PhD⁸, Daniel Arber⁹, Yangming Zhang, MD¹⁰^*, Jacob M. Rowe, MD¹¹, John E. Godwin, MD, MS¹², Jessica K. Altman, MD¹³, Selina Luger, MD¹⁴, Aref Al-Kali, MD¹⁵, Hong Zheng, MD, PhD¹⁶, Keith Pratz, MD¹⁷, E. Randolph Broun, MD¹⁸, Bayard L. Powell, MD¹⁹, Kristen O'Dwyer, MD²⁰^*, Mark R Litzow, MD²¹ and Martin S Tallman, MD⁷

¹Mayo Clinic Cancer Center, Jacksonville, FL
²Dana-Farber Cancer Institute, Boston, MA
³Penn State Hershey Cancer Institute, Hershey, PA
⁴Ireland Cancer Center, University Hospitals of Cleveland Case Medical Center, Cleveland, OH
⁵VA Palo Alto Health Care System, Palo Alto, CA
⁶Department of Medicine, Weill Cornell Medical College, New York, NY
⁷Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Cancer Center, The North Division of Montefiore Medical Center, Bronx, NY
⁹Department of Pathology, Stanford University School of Medicine, Palo Alto, CA
¹⁰Cytogenetics, Northwestern University, Chicago, IL
¹¹Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
¹²Providence Onc/Hem Care Clinic, Portland, OR
¹³Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
¹⁴Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
¹⁵Mayo Clinic, Rochester, MN
¹⁶Department of Medicine, Penn State Hershey Medical Center, Hershey, PA
¹⁷Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
¹⁸The Jewish Hospital, Cincinnati, OH
¹⁹Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
²⁰James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
²¹Division of Hematology, Mayo Clinic, Rochester, MN

9:45 AM

218

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

Xavier Thomas¹, Stéphane De Botton²^*, Sylvie Chevret³^*, Denis Caillot⁴^*, Emmanuel Raffoux⁵^*, Emilie Lemasle⁶^*, Jean-Pierre Marolleau⁷, Céline Berthon⁸^*, Arnaud Pigneux⁹^*, Norbert Vey¹⁰, Oumedaly Reman¹¹, Marc Simon¹²^*, Christian Recher¹³, Jean-Yves Cahn¹⁴, Olivier Hermine¹⁵^*, Sylvie Castaigne¹⁶, Karine Celli-Lebras¹⁷^*, Claude Preudhomme¹⁸, Christine Terré¹⁹^* and Hervé Dombret⁵

¹Hematology, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
²Gustave Roussy Cancer Center, Villejuif, France
³Biostatistics department, Hôpital Saint-Louis, Paris, France
⁴Hôpital du Bocage, Dijon, France
⁵Hematology, Hôpital Saint-Louis, Paris, France
⁶Hematology, Centre Henri Becquerel, Rouen, France
⁷Hematology, Hôpital Sud, Amiens, France
⁸Hematology, CHRU, Lille, France
⁹Hematology, Hôpital Haut Lêveque, Pessac, France
¹⁰Hematology, Institut Paoli-Calmettes, Marseille, France
¹¹Hematology, CHU, Caen, France
¹²Hematology, Centre Hospitalier, Valenciennes, France
¹³Hematology, Institut Universitaire du Cancer, Toulouse, France
¹⁴Hematology, Hôpital Michallon, Grenoble, France
¹⁵Hematology, Hôpital Necker Enfants Malades, Paris, France
¹⁶Hematology, Hôpital Mignot, Le Chesnay, France
¹⁷ALFA Coordination, Hôpital Saint-Louis, Paris, France
¹⁸Hematology Laboratory, CHRU, Lille, France
¹⁹Hematology Laboratory, CH, Versailles, France

10:00 AM

219

Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

Matthew A. Kutny, MD¹, Todd A. Alonzo, PhD², Robert B. Gerbing, MA³^*, Yi-Cheng Wang, MS³^*, Cecilia Fu, MD⁴, Soheil Meshinchi, MD, PhD⁵, Alan S. Gamis, MD, MPH⁶, James H. Feusner, MD⁷^* and John Gregory Jr., MD⁸

¹Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL
²Keck School of Medicine, University of Southern California, Los Angeles, CA
³Children's Oncology Group, Monrovia, CA
⁴Division of Hematology/Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA
⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁶Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO
⁷Division of Hematology/Oncology, Children's Hospital and Research Center Oakland, Oakland, CA
⁸Atlantic Health System, Goryeb Children's Hospital, Morristown, NJ

10:15 AM

220

Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Jianxiang Wang, MD, PhD¹, Yingchang Mi, MD, PhD², Bin Jiang³^*, Xiequn Chen⁴^*, Chunyan Ji, MD, PhD⁵^*, Yan Li⁶^*, Xielan Zhao⁷^*, Yongrong Lai⁸^*, Yu Hu, M.D., Ph.D.⁹^*, Aiping Tang¹⁰^*, Ting Liu, MD, PhD¹¹, Jie Jin, MD, PhD¹², Junmin Li¹³^*, Linhua Yang¹⁴^*, Jianyong Li, MD, PhD¹⁵ and Fanyi Meng¹⁶

¹Institute of Hematology, Hospital of Blood Diseases, CAMS, Tianjin, China
²State Key Laboratory of Experimental Hematology, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
⁴Xijing Hospital of the Fourth Military Medical University, Xian, China
⁵Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
⁶The First Hospital Affiliated of China Medical University, Shenyang, China
⁷The Xiangya Hospital of Central-South University, Changsha, China
⁸The First Affiliated Hospital of Guangxi Medical University, Nanning, China
⁹Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
¹⁰The Second Affiliated Hospital of Nanchang University, Nanchang, China
¹¹Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
¹²Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
¹³Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China
¹⁴The Second Hospital of Shanxi Medical University, Taiyuan, China
¹⁵Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
¹⁶Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

10:30 AM

221

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD¹, Robert K Hills, DPhil², Sylvie Freeman, PhD FRCPath³^*, Steven Knapper⁴, Lars Kjeldsen, MD, PhD⁵, Ian Thomas⁶^*, Jamie Cavenagh⁷, Paul Cahalin⁸^*, Mary Frances McMullin, MD, FRCPath, FRCP⁹ and Alan K. Burnett, MD, FRCP¹⁰

¹Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom
²Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom
³Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
⁴Cardiff University, Cardiff, United Kingdom
⁵Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁶HCTU, Cardiff University, Cardiff, United Kingdom
⁷Dept. of Hematology, St. Bartholomew's Hospital, London, United Kingdom
⁸Blackpool Victoria Hospital, Blackpool, United Kingdom
⁹Queen's University Belfast, Belfast, United Kingdom
¹⁰Blackwaterfoot, Isle of Arran, United Kingdom

10:45 AM

222

Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial

Christoph Röllig, MD¹^*, Michael Kramer, MSc.²^*, Maria Gabrecht³^*, Mathias Hänel⁴^*, Regina Herbst, MD⁵^*, Ulrich Kaiser⁶^*, Norbert Schmitz, M.D. Ph.D.⁷, Johannes Kullmer⁸^*, Sebastian Fetscher⁹^*, Hartmut Link, MD, PhD¹⁰^*, Luisa Mantovani-Löffler¹¹^*, Ulrich Krümpelmann¹²^*, Thomas Neuhaus¹³^*, Frank Heits¹⁴^*, Hermann Einsele¹⁵, Barbara Ritter¹⁶^*, Martin Bornhäuser, MD¹^*, Johannes Schetelig, MD, M.Sc^17,18, Christian Thiede, MD¹⁹, Brigitte Mohr³^*, Markus Schaich, MD²⁰, Uwe Platzbecker, MD²¹, Kerstin Schäfer-Eckart²²^*, Alwin Krämer²³^*, Wolfgang E Berdel, MD²⁴, Hubert Serve, MD²⁵^*, Gerhard Ehninger, MD¹⁷ and Ulrich S. Schuler, MD^3,26^*

¹Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
²Medical Dept. 1, University Hospital TU Dresden, Dresden, Germany
³Universitätsklinikum TU Dresden, Dresden, Germany
⁴Klinik für Innere Medizin III, Klinikum, Chemnitz, Germany
⁵Klinikum Chemnitz, Chemnitz, Germany
⁶St. Bernward Krankenhaus, Hildesheim, Germany
⁷Asklepios Klinik St. Georg, Hamburg, Germany
⁸DIAKO Bremen, Bremen, Germany
⁹Sana Kliniken, Lübeck, Germany
¹⁰Klinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern, Germany
¹¹St. Georg, Leipzig, Germany
¹²Klinikum Bielefeld, Bielefeld, Germany
¹³St. Vincenz Krankenhaus, Limburg, Germany
¹⁴Agaplesion Diakonieklinikum, Rotenburg, Germany
¹⁵2Department of Internal Medicine. II, Wuerzburg, Germany
¹⁶Klinikum Kassel, Kassel, Germany
¹⁷Medizinische Klinik I, Universitaetsklinikum C.G.Carus, Dresden, Germany
¹⁸DKMS German Bone Marrow Donor Center, Dresden, Germany
¹⁹Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
²⁰Klinik für Hämatologie und Onkologie, Rems-Murr-Klinikum Winnenden, Winnenden, Germany
²¹Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
²²Klinikum Nord, Nürnberg, Germany
²³Universitätsklinikum Heidelberg, Heidelberg, Germany
²⁴Department of Medicine A, University Hospital Münster, Muenster, Germany
²⁵Dept. of Internal Medicine, University Hospital of Frankfurt, Frankfurt, Germany
²⁶Study Alliance Leukemia SAL, Dresden, Germany

See more of: Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

615.O1.6 615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: New Approaches Using Older Drugs